322
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Benzodiazepine Usage, Healthcare Resource Utilization, and Costs Among Older Adults Treated with Common Insomnia Medications: A Retrospective Cohort Study

, ORCID Icon, , &
Pages 413-424 | Received 27 Jan 2023, Accepted 29 May 2023, Published online: 02 Jun 2023

References

  • Ancoli-Israel S. Sleep and its disorders in aging populations. Sleep Med. 2009;10(Suppl 1):S7–S11. doi:10.1016/j.sleep.2009.07.004
  • Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010. Pharmacoepidemiol Drug Saf. 2016;25(6):637–645. doi:10.1002/pds.3951
  • Maust DT, Blow FC, Wiechers IR, Kales HC, Marcus SC. National trends in antidepressant, benzodiazepine, and other sedative-hypnotic treatment of older adults in psychiatric and primary care. J Clin Psychiatry. 2017;78(4):e363–e71. doi:10.4088/JCP.16m10713
  • Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136–142. doi:10.1001/jamapsychiatry.2014.1763
  • American Psychiatric A, American Psychiatric Association DSMTF. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013:947.
  • Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989;262(11):1479–1484. doi:10.1001/jama.1989.03430110069030
  • Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep Med Rev. 2019;43:96–105. doi:10.1016/j.smrv.2018.10.006
  • Taylor DJ, Lichstein KL, Durrence HH. Insomnia as a health risk factor. Behav Sleep Med. 2003;1(4):227–247. doi:10.1207/S15402010BSM0104_5
  • Pollack M, Seal B, Joish VN, Cziraky MJ. Insomnia-related comorbidities and economic costs among a commercially insured population in the United States. Curr Med Res Opin. 2009;25(8):1901–1911. doi:10.1185/03007990903035505
  • Wickwire EM, Shaya FT, Scharf SM. Health economics of insomnia treatments: the return on investment for a good night’s sleep. Sleep Med Rev. 2016;30:72–82. doi:10.1016/j.smrv.2015.11.004
  • Tzuang M, Owusu JT, Huang J, et al. Associations of insomnia symptoms with subsequent health services use among community-dwelling US older adults. Sleep. 2021;44(5). doi:10.1093/sleep/zsaa251
  • Kaufmann CN, Canham SL, Mojtabai R, et al. Insomnia and health services utilization in middle-aged and older adults: results from the health and retirement study. J Gerontol a Biol Sci Med Sci. 2013;68(12):1512–1517. doi:10.1093/gerona/glt050
  • Wickwire EM, Tom SE, Scharf SM, Vadlamani A, Bulatao IG, Albrecht JS. Untreated insomnia increases all-cause health care utilization and costs among medicare beneficiaries. Sleep. 2019;42(4). doi:10.1093/sleep/zsz007
  • Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2016;165(2):125–133.
  • Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255–262. doi:10.5664/jcsm.8986
  • National Institutes of H. National institutes of health state of the science conference statement on manifestations and management of chronic insomnia in adults. Sleep. 2005;28(9):1049–1057. doi:10.1093/sleep/28.9.1049
  • VA/DoD. The management of chronic insomnia disorder and obstructive sleep apnea (Insomnia/OSA). Available from: https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp2019. Accessed May 30, 2023.
  • Wilson SJ, Nutt DJ, Alford C, et al. British Association for psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24(11):1577–1601. doi:10.1177/0269881110379307
  • Thomas A, Grandner M, Nowakowski S, Nesom G, Corbitt C, Perlis ML. Where are the behavioral sleep medicine providers and where are they needed? A geographic assessment. Behav Sleep Med. 2016;14(6):687–698. doi:10.1080/15402002.2016.1173551
  • Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999–2010. Sleep. 2014;37(2):343–349. doi:10.5665/sleep.3410
  • Diaz-Gutierrez MJ, Martinez-Cengotitabengoa M, Saez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas. 2017;101:17–22. doi:10.1016/j.maturitas.2017.04.002
  • Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66(Suppl 2):9–13.
  • Panel BtAGSBCUE. American geriatrics society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–694. doi:10.1111/jgs.15767
  • Amari DT, Juday T, Frech FH, et al. Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines. BMC Geriatr. 2022;22(1):484. doi:10.1186/s12877-022-03165-6
  • Wickwire EM, Amari DT, Juday TR, Frech F, Gor D, Malhotra M. Incremental health care resource use and costs among adult patients with depression and treated for insomnia with zolpidem, trazodone, or benzodiazepines. Curr Med Res Opin. 2022;38(5):711–720. doi:10.1080/03007995.2022.2047537
  • Tom SE, Wickwire EM, Park Y, Albrecht JS. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep. 2016;39(5):1009–1014. doi:10.5665/sleep.5742
  • Albrecht JS, Wickwire EM, Vadlamani A, Scharf SM, Tom SE. Trends in insomnia diagnosis and treatment among medicare beneficiaries, 2006–2013. Am J Geriatr Psychiatry. 2019;27(3):301–309. doi:10.1016/j.jagp.2018.10.017
  • Wong J, Murray Horwitz M, Bertisch SM, Herzig SJ, Buysse DJ, Toh S. Trends in dispensing of zolpidem and low-dose trazodone among commercially insured adults in the United States, 2011–2018. JAMA. 2020;324(21):2211–2213. doi:10.1001/jama.2020.19224
  • Abrahamowicz M, Bartlett G, Tamblyn R, du Berger R. Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. J Clin Epidemiol. 2006;59(4):393–403. doi:10.1016/j.jclinepi.2005.01.021
  • Sylvestre MP, Abrahamowicz M, Čapek R, Tamblyn R. Assessing the cumulative effects of exposure to selected benzodiazepines on the risk of fall-related injuries in the elderly. Int Psychogeriatr. 2012;24(4):577–586. doi:10.1017/S1041610211002031
  • Neubauer DN, Pandi-Perumal SR, Spence DW, Buttoo K, Monti JM. Pharmacotherapy of insomnia. J Cent Nerv Syst Dis. 2018;10:1179573518770672. doi:10.1177/1179573518770672
  • Newton RE. The side effect profile of trazodone in comparison to an active control and placebo. J Clin Psychopharmacol. 1981;1:89S–93S. doi:10.1097/00004714-198111001-00016
  • Wickwire EM, Vadlamani A, Tom SE, Johnson AM, Scharf SM, Albrecht JS. Economic aspects of insomnia medication treatment among medicare beneficiaries. Sleep. 2020;43(1):zsz192.
  • Wickwire EM. Value-based sleep in the workplace. Sleep. 2016;39(10):1767–1768. doi:10.5665/sleep.6150